Obesity – Kailera K9531-3107

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

Key Inclusion Criteria:

  • BMI ≥35 kilograms per square meter (kg/m^2).
  • History of at least 1 self-reported unsuccessful effort to lose weight with diet and exercise within the prior 6 months.
  • Other criteria may apply

Call us or complete the form and our team will reach out soon to help determine your eligibility.

  • California: 619-489-5613
  • Michigan: 248-282-3640
View Study on ClinicalTrials.gov

Trial Interest Form

Locations

Michigan Healthcare Professionals TriAtria

32255 Northwestern Hwy
Suites 130 & 160
Farmington Hills, Michigan

Tri-City Medical Center - Seaside Medical Group

115 N El Camino Real
Suite A
Oceanside, California